Autolus Therapeutics plc AUTL
1.24 USD -0.08 (-6.44%)
At closeNov 11, 2026, 7:53 PM EST
1.23 -0.01 -0.40%
After hours · Nov 11, 7:53 PM ET
1.20 Day range 1.33
1.12 52-week range 2.58
- YTD
- -37.94%
- 1 year
- -17.67%
News
benzinga.com Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline Fonger-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), was presented today during…
globenewswire.com Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline In 15 patients evaluable for safety, obe-cel…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q3 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL raised its full-year AUCATZYL sales outlook after third-quarter revenue nearly doubled from a year earlier, as the company reported improved manufacturing margins…
benzinga.com Autolus Therapeutics Q3 2026 Earnings Call Transcript Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.
benzinga.com Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 30 percent increase over losses of…
globenewswire.com Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at…
globenewswire.com Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference LONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…- benzinga.com Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Abstract 4498 – Oral PresentationTitle: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia…
globenewswire.com Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
globenewswire.com Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
benzinga.com HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.
seekingalpha.com Autolus Therapeutics: Key Questions For The Near Term Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing autoimmune pipeline catalysts. Q2 2026 saw product revenue rise to $45.7M, with net loss narrowing and…
globenewswire.com Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…
zacks.com All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today…
globenewswire.com Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
defenseworld.net Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
benzinga.com The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of…
globenewswire.com Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q2 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year…- benzinga.com Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
- benzinga.com Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses…
globenewswire.com Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering…- benzinga.com HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.- benzinga.com Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-dateFY 2026 sales guidance increased to $140 – $150…
globenewswire.com Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150…
seekingalpha.com Autolus Therapeutics: Navigating A Bumpy 2026 Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis…
zacks.com 3 Cancer Stocks to Watch as Oncology Innovation Accelerates Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
globenewswire.com Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
benzinga.com HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10 HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.
benzinga.com Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.062 million analyst estimate.- benzinga.com Autolus Therapeutics Q1 EPS $(0.27), Inline, Sales $26.218M Beat $26.160M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Autolus Therapeutics Plans To Cut Workforce By ~13% As Part Of Initiative To Enhance Operational Efficiency, Lower Operating Expenses Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today…
benzinga.com Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.- benzinga.com Earnings Scheduled For March 27, 2026
benzinga.com Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
benzinga.com DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday 
benzinga.com Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday 
benzinga.com Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 12, 2025